Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration | Zendy

Ciro Costagliola | Zendy; Mary Romano | Zendy; Michele Rinaldi | Zendy; Roberto dell’Omo | Zendy; Flavia Chiosi | Zendy; M. Menzione | Zendy; Francesco Semeraro | Zendy

Open Access

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

Author(s) -

Ciro Costagliola,

Mary Romano,

Michele Rinaldi,

Roberto dell’Omo,

Flavia Chiosi,

M. Menzione,

Francesco Semeraro

Publication year - 2009

Publication title -

british journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.016

H-Index - 153

eISSN - 1468-2079

pISSN - 0007-1161

DOI - 10.1136/bjo.2009.159343

Subject(s) - verteporfin , medicine , macular degeneration , photodynamic therapy , ophthalmology , visual acuity , bevacizumab , choroidal neovascularization , surgery , chemotherapy , chemistry , organic chemistry

To report the efficacy and safety of intravitreal bevacizumab (IVB) alone versus IVB plus low-fluence photodynamic therapy (PDT) in age-related macular degeneration (AMD) patients and to verify the occurrence of a synergistic effect of the combined approach on visual acuity, size and morphology of lesion, as well as on the treatment rate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research